Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

608
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
608
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

659
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
659
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

920
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
920
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

616
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
616
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

1.4K
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
1.4K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

732
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
732

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Automatic Evaluation of Small Bowel Cleanliness in Capsule Endoscopy: A Comparative Study of Four Preparations using Artificial Intelligence.

Endoscopy international open·2026
Same author

Real-World Effectiveness of Risankizumab in Refractory Crohn's Disease: The RISANCROHN Study From the ENEIDA Registry.

Alimentary pharmacology & therapeutics·2026
Same author

Training satisfaction, competency gaps and well-being in gastroenterology residency in Spain: results of a national SEPD survey.

BMC gastroenterology·2026
Same author

Th1/Th17 cytokine signatures correlate with Crohn's disease activity in a 54‑week cohort of patients treated with adalimumab.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same author

Biological therapies for inflammatory pouch disorders: insights and outcomes from the RESERVO study of GETECCU.

Therapeutic advances in gastroenterology·2026
Same author

Long-term clinical outcomes with filgotinib in ulcerative colitis: 12-month results from the FILGUITO study.

World journal of gastroenterology·2026

Related Experiment Video

Updated: Mar 26, 2026

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
07:38

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Published on: September 13, 2016

8.8K

Initial experience with golimumab in clinical practice for ulcerative colitis.

Luisa Castro-Laria1, Federico Argüelles-Arias2, Valle García-Sánchez3

  • 1Digestivo, H Universitario Virgen Macarena, España.

Revista Espanola De Enfermedades Digestivas
|January 21, 2016
PubMed
Summary

Golimumab is an effective and safe treatment for ulcerative colitis patients, regardless of prior anti-TNF therapy. This study shows high response rates and corticosteroid withdrawal in both naive and non-naive patients.

More Related Videos

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
06:19

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Published on: May 16, 2025

2.1K
Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
07:06

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

27.8K

Related Experiment Videos

Last Updated: Mar 26, 2026

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
07:38

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Published on: September 13, 2016

8.8K
Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
06:19

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Published on: May 16, 2025

2.1K
Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
07:06

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

27.8K

Area of Science:

  • Gastroenterology
  • Immunology
  • Pharmacology

Background:

  • Golimumab is a tumor necrosis factor (TNF)-blocking agent.
  • It is indicated as a second-line therapy for ulcerative colitis.

Purpose of the Study:

  • To evaluate the effectiveness and safety of golimumab in ulcerative colitis patients within a clinical setting.
  • To assess golimumab's efficacy in both anti-TNF naive and non-naive patient populations.

Main Methods:

  • A retrospective study involving 23 ulcerative colitis patients.
  • Patients received golimumab induction therapy (200 mg at week 0, 100 mg at week 2) followed by maintenance doses (50 mg or 100 mg every 4 weeks based on body weight).

Main Results:

  • The study included 7 anti-TNF naive and 16 non-naive patients, with an average treatment duration of 14.3 weeks.
  • Corticosteroid withdrawal was achieved in 74% of patients.
  • Clinical response rates were 85.5% in naive patients and 75% in non-naive patients.

Conclusions:

  • Golimumab demonstrates potential as an alternative treatment for both naive and non-naive ulcerative colitis patients.
  • The therapy was found to be safe, with no adverse effects reported in the studied cohort.